Web-Based Visual Field Test for Glaucoma

Overseen By Andrew Pouw, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Andrew Pouw, MD

Disqualifiers: Non-English, Central vision disease, Neurocognitive, Psychiatric, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Approved in 1 Jurisdiction This treatment is already approved in other countries

Compensation: Varies

Number of Visits: Unknown

Duration: 24 weeks

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to assess how well patients adhere to a routine of checking their vision at home using a new web-based tool called EyeSimplify, a visual field test. Designed for individuals diagnosed with or suspecting glaucoma—a condition that damages the optic nerve and can lead to vision loss—participants will use an iPad to test their vision every two weeks for six months. Researchers seek to determine the test's ease of use and its ability to detect vision changes consistent with standard office tests. This trial suits those with glaucoma who can easily use technology at home. As an unphased trial, it offers a unique opportunity to contribute to innovative research that could enhance home-based glaucoma monitoring.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It seems focused on testing a new visual field test for glaucoma, so it's unlikely that your current medications would be affected.

What prior data suggests that this web-based visual field test is safe for at-home use?

Research has shown that home-based eye tests like EyeSimplify reliably check for glaucoma, similar to traditional methods. Studies have not reported any negative side effects or problems. EyeSimplify, primarily a software tool used on an iPad, involves no physical procedures, making it a low-risk option for participants. As an online eye test, safety concerns are minimal, with the focus more on ease of use and accuracy than on physical safety. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about the EyeSimplify web-browser-based visual field test because it offers a new, more accessible way to monitor glaucoma. Unlike traditional visual field tests, which often require a visit to a specialized clinic with expensive equipment, EyeSimplify can be administered from the comfort of your own home using just a computer and internet connection. This approach not only saves time and reduces the burden of frequent clinic visits but also allows for more consistent monitoring, which is crucial for managing a condition like glaucoma. Additionally, the convenience of a web-based test could improve patient compliance and lead to better long-term outcomes.

What evidence suggests that the EyeSimplify web-based visual field test is effective for glaucoma?

Research has shown that home-based eye tests like EyeSimplify, which participants in this trial will use, can reliably check for glaucoma, similar to traditional methods. One study found that these online tests provide results comparable to standard tests conducted in a doctor's office, making them a promising option. Additionally, these tests are easy to use at home and cost less, allowing for regular use. Previous studies have demonstrated that these tests can successfully identify moderate to advanced glaucoma. This suggests that EyeSimplify could detect vision changes related to glaucoma as effectively as tests performed in a doctor's office. ^{1 2 3 6 7}

Who Is on the Research Team?

Andrew Pouw, MD

Principal Investigator

University of Iowa

Are You a Good Fit for This Trial?

This trial is for glaucoma patients aged 18-100 who speak English and have a visual acuity of at least 20/80. It's not suitable for those with severe astigmatism, central vision-affecting diseases, or neurocognitive/psychiatric disorders that could interfere with testing.

Exclusion Criteria

Patients with best corrected visual acuity less than 20/80

I have a condition that affects my central vision.

Patients with astigmatism with absolute values greater than 2.00 diopters

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants perform at-home visual field tests using the EyeSimplify platform biweekly for six months

24 weeks

Biweekly at-home tests

Follow-up

Participants are monitored for adherence and user experience feedback after the treatment period

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• EyeSimplify web-browser-based visual field test

Trial Overview The study tests the EyeSimplify web-based visual field test on iPads to see if patients will stick to biweekly home testing over six months and how it compares to standard office-based tests in detecting glaucoma progression.

How Is the Trial Designed?

Group I: Single Arm Experimental Treatment 1 Intervention

All patients will be in a single arm: patients will have one or both eyes (dependent on inclusion/exclusion criteria) tested with the EyeSimplify visual field test biweekly for 6 months.

EyeSimplify web-browser-based visual field test is already approved in United States for the following indications:

Approved in United States as EyeSimplify for:

• Glaucoma-related visual field testing

Who Is Running the Clinical Trial?

Andrew Pouw, MD

Lead Sponsor

Trials

2

Recruited

70+

Published Research Related to This Trial

A new home-based visual field examination method using a PC monitor or virtual reality glasses shows promise for glaucoma screening, demonstrating a good receiver operating characteristic curve (0.762 to 0.837) when compared to the standard Humphrey perimeter.

The method allows for self-testing and analysis of visual field results without specialized equipment, making it a potentially accessible option for early glaucoma detection, with sensitivity ranging from 0.637 to 0.942.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Home-based visual field test for glaucoma screening comparison with Humphrey perimeter. Tsapakis, S., Papaconstantinou, D., Diagourtas, A., et al.[2022]

Specvis is a free and open-source application designed for visual field examination, which can run on any personal computer, making it an accessible tool for diagnosing visual impairments, especially in underdeveloped regions.

In validation studies involving patients with glaucoma, retinitis pigmentosa, and stroke, Specvis demonstrated low variability and reliable results compared to the Medmont M700 Automated Static Perimeter, indicating it can effectively identify areas of visual field impairment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Specvis: Free and open-source software for visual field examination. Dzwiniel, P., Gola, M., Wójcik-Gryciuk, A., et al.[2019]

Remote training for glaucoma patients to use the Vivid Vision Perimetry (VVP-10) test at home is feasible, with 95% of participants successfully completing the test series after just one training session.

The VVP-10 showed excellent test-retest reliability (ICC of 0.95) and strong correlation with conventional perimetry results, suggesting it could be a reliable alternative for assessing visual function in glaucoma patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Assessment of Remote Training, At-Home Testing, and Test-Retest Variability of a Novel Test for Clustered Virtual Reality Perimetry. Chia, ZK., Kong, AW., Turner, ML., et al.[2023]

The novel visual field application on a portable augmented-reality headset shows excellent correlation with the standard Humphrey field analyzer, with a Pearson correlation coefficient of 0.94 for mean sensitivity and 0.95 for mean deviation, based on a study of 89 patients.

The analysis indicates that the Heru visual field test has a small mean difference compared to the Humphrey test, suggesting it is a reliable alternative for assessing visual fields in patients with and without glaucoma.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Comparison of Visual Field Test Measurements With a Novel Approach on a Wearable Headset to Standard Automated Perimetry. Johnson, C., Sayed, A., McSoley, J., et al.[2023]

The Damato Multifixation Campimetry Online (DMCO) test shows high specificity (up to 98.1%) and varying sensitivity for detecting glaucomatous visual field loss, with 100% sensitivity for advanced and severe glaucoma cases, based on a study of 97 individuals.

The most effective interpretation algorithm for DMCO results was found by combining two successive DMCO STANDARD tests, indicating that this online tool could be a valuable resource for glaucoma detection, especially in a preselected population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Glaucoma detection with damato multifixation campimetry online. Olsen, AS., Alberti, M., Serup, L., et al.[2018]

In a study of 79 participants with glaucoma or ocular hypertension, the tablet-based Melbourne Rapid Fields (MRF) and the IMOvifa Smart Visual Function Analyzer (SVFA) showed similar average mean deviation (MD) values to the Humphrey Field Analyzer (HFA), suggesting they can be viable alternatives for visual field testing.

However, significant differences in point sensitivity were observed, particularly with the MRF tablet overestimating sensitivity in the nasal field and underestimating it in the temporal field, indicating that while these devices may be useful for at-home monitoring, their results may vary significantly at specific locations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Comparison of Perimetric Outcomes from a Tablet Perimeter, Smart Visual Function Analyzer, and Humphrey Field Analyzer. Kang, J., De Arrigunaga, S., Freeman, SE., et al.[2023]

Citations

1. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC12306691/

Comparative Analysis of Melbourne Rapid Fields Web ... This study aims to evaluate the efficacy and practicality of the Melbourne Rapid Fields (MRF) web-browser based perimeter software, ...

2. clinicaltrials.gov clinicaltrials.gov/study/NCT05690152

Persistence of Glaucoma Patients With Web-Browser ... The purpose of this prospective study is to assess patient persistence and adherence with a 6-month period of at-home visual field testing using an iPad with a ...

3. withpower.com withpower.com/trial/phase-glaucoma-2023-515b2

Web-Based Visual Field Test for Glaucoma Research shows that home-based visual field tests, like EyeSimplify, can be reliable for glaucoma screening when compared to traditional methods. Studies have ...

4. frontiersin.org frontiersin.org/journals/ophthalmology/articles/10.3389/fopht.2025.1485950/full

Multi-centre comparison between device-independent web ... MRF-web produces outcomes comparable to HFA SITA-Faster. Its portability and cost-effectiveness suggest suitability as an alternative method for visual field ...

5. ophthalmologyglaucoma.org ophthalmologyglaucoma.org/article/S2589-4196(21)00206-4/fulltext

Glaucoma Screening Using an iPad-Based Visual Field ... The MRF showed potential for screening in a low-resource setting, particularly for detecting moderate to advanced glaucoma.

6. vftest.eyesimplify.com vftest.eyesimplify.com/

MRF Account Page MRF visual field software provides a portable, rapid and accurate threshold testing of visual field for patients with eye and neurological conditions.

7. drchia.com drchia.com/homevf

EyeSimplify Visual Fields at Home The EyeSimplify MRF at Home is the first web-based visual field test that uses published and peer-reviewed testing algorithms to provide a convenient way to ...